Harmony Biosciences Holdings, Inc. will present six abstracts focused on narcolepsy and idiopathic hypersomnia at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS). The event is scheduled to take place in Baltimore, MD, from June 14 to June 17. The presentations will include data on treatments such as Pitolisant, HBS-301, and HBS-201, reflecting the company's ongoing research in rare neurological diseases.

The accepted abstracts include a pooled analysis of Pitolisant treatment in adults with narcolepsy and an analysis of Phase 3 trial sleep diary data regarding the drug's effect on sleep patterns in idiopathic hypersomnia. Additionally, the company will present findings from Phase 3, randomized, double-blind, placebo-controlled studies of HBS-301 for both narcolepsy and idiopathic hypersomnia.

Further presentations will detail results from a Phase 1b clinical trial on the dosing optimization of the Pitolisant gastro-resistant formulation (HBS-201) in adults with narcolepsy. A cross-sectional study regarding patient experience of fatigue and assessment in narcolepsy is also on the agenda. The final poster will cover the long-term safety and effectiveness of Pitolisant in adult patients with idiopathic hypersomnia, presenting final results from an open-label Phase 3 trial.

Presentation Schedule

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. The company was established by Paragon Biosciences, LLC, in 2017 and is headquartered in Plymouth Meeting, Pa.